Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer
- 1 April 2005
- journal article
- presidential symposium
- Published by Springer Nature in Breast Cancer
- Vol. 12 (2) , 73-85
- https://doi.org/10.1007/bf02966817
Abstract
Individualized selection of the most effective adjuvant (or neoadjuvant) chemotherapy for breast cancer based on the molecular characteristics of the tumor could improve the risk:benefit ratio of current therapies. It could also streamline the development of new regimens for those who are unlikely to benefit from existing drugs. It is expected that combinations of markers will be more informative to predict response than any single gene and may yield regimen-specific predictors. Novel molecular analytical tools, particularly transcriptional profiling, provide a method to test this hypothesis. Several small exploratory studies have shown encouraging results. This article reviews recent progress in this field including experience from the breast cancer pharmacogenomic marker discovery program at the Nellie B. Connally Breast Center of the University of Texas M. D. Anderson Cancer Center. This manuscript is based on a presentation that was given during the Presidential Symposium of the annual meeting of the Japanese Breast Cancer Society in 2004.Keywords
This publication has 30 references indexed in Scilit:
- Clinical trial design for microarray predictive marker discovery and assessmentAnnals of Oncology, 2004
- Immediate Gene Expression Changes After the First Course of Neoadjuvant Chemotherapy in Patients with Primary Breast Cancer DiseaseClinical Cancer Research, 2004
- Cross-site comparison of gene expression data reveals high similarity.Environmental Health Perspectives, 2004
- Clofibrate-induced gene expression changes in rat liver: a cross-laboratory analysis using membrane cDNA arrays.Environmental Health Perspectives, 2004
- Evaluation of gene expression measurements from commercial microarray platformsNucleic Acids Research, 2003
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences, 2003
- Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-valuesBioinformatics, 2003
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- Estimating Dataset Size Requirements for Classifying DNA Microarray DataJournal of Computational Biology, 2003